InnovationRx: Medical Debts Will Be Erased From Credit Histories
In this edition of InnovationRx, medical debts will be erased from credit histories, this farm is doubling down on raw milk ...
GlobalData on MSN1d
J&J reports positive topline outcomes from Phase III NSCLC combo therapy trial
Johnson & Johnson (J&J) has reported positive topline outcomes from the Phase III MARIPOSA trial of Rybrevant ...
'Nonsense!' Dame Esther Rantzen hits back at assisted dying critic
Dame Esther responded after a columnist tried to use her own cancer experience as an argument against assisted dying.
oncnursingnews6d
Evaluating Targeted Therapies: MARIPOSA Trial Aids APPs in Treating EGFR+ NSCLC
Beth Sandy, MSN, CRNP, FAPO, led a discussion on EGFR-mutated non-small cell lung cancer, focusing on targeted therapies for ...
Esther Rantzen fought for ‘assisted dying’. Now she’s surely killed it off
The other day, Dame Esther Rantzen announced some wonderful news. In an article she’d written for a national newspaper, ...
Cullinan Therapeutics: Casting A Wide Net With Their Pipeline
Cullinan Therapeutics’ strong financial position funds growth into 2028. Find out why CGEM stock presents a compelling buy ...
stocknews1d
3 Blue-Chip Stocks with Strong Buy Ratings from Analysts
As a wave of volatility has been re-introduced to the system, investors are flocking toward blue-chip companies for stability ...
Becker's Hospital Review1d
Drug extends survival in lung cancer patients: J&J
Johnson & Johnson released results from a phase 3 study, showing that the combination of Rybrevant and Lazcluze significantly improved overall survival in patients with advanced non-small cell lung ...
MedPage Today29d
Lung Cancer Drug Osimertinib Tied to Cardiac Events, Even in Low-Risk Patients
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The non-small cell lung cancer (NSCLC) drug osimertinib (Tagrisso) was associated with an increased risk of therapy ...
GlobalData on MSN6d
China’s NMPA prioritises HUTCHMED’s lung cancer therapy review
China National Medical Products Administration (NMPA) has granted acceptance and priority review for the new drug application ...
Johnson & Johnson’s rybrevant plus lazcluze improve survival in lung cancer
Johnson & Johnson announced positive topline results for the gold standard endpoint in cancer treatment of overall survival, or OS, from ...
PharmaTimes7d
EC approves Rybrevant with Lazcluze for advanced lung cancer
Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Commission has approved Rybrevant ...